Anupam Rasayan India Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/08rejeb69n2z77wfhh26jxi1.pdf

Key Takeaways


Demand Environment & Europe+1 Strategy

Anand Desai: "This has been in the works since last 1.5 years to 2 years. But with the Europe-plus-one situation, this has got an added urgency from the customer side now."

CapEx Program & Capacity Expansion

Vishal Thakkar: "They should be better, but let's look at similar margins for now and then we can see as we go."

Working Capital & Cash Flow


Customer & Revenue Profile

Anand Desai: "Anupam has been known to be a fair supplier, we do not take advantage of any manufacturer issues in Europe or anywhere else. We have always tried to see our customer benefits, not our benefit because that is what pays off in the longer term."

Tanfac Consolidation & Financial Mechanics


Fire Incident


Guidance & Commitments

CommitmentSpecificsTimeline
CapEx completion₹670 crores total program18–24 months from now
CapEx ramp-up to target asset turn1.75x minimum asset turnover on new capital2–2.5 years from commissioning (~4–4.5 years total)
Working capitalReturn toward historical inventory levelsBy year-end
FY23 CapExAround ₹250 croresFY23
FY24 CapExAround ₹350–400 crores (to be refined)FY24, with more clarity next quarter
ROCE target20%-plusOngoing
New products from Europe+120–25 niche products added to portfolioNear term
Fluorination revenue potential₹220–260 crores at full potentialLonger period

Key Metrics

MetricQ2 FY23
Standalone operating revenue₹310.7 cr, up 25% YoY from ₹248.9 cr
Consolidated operating revenue₹386.2 cr, up 55% YoY from ₹248.9 cr
Standalone EBITDA₹89.8 cr, up 29% YoY from ₹69.7 cr
Standalone EBITDA margin29%
Consolidated EBITDA₹101.2 cr, up 44% YoY from ₹70.2 cr
Consolidated PAT₹47.8 cr, up 33% YoY from ₹36.1 cr
Life science segment revenue₹277 cr, 90% of total revenue
Exports share69% of revenue
Revenue from top 10 customers83% of total revenue, across 24 products
Total products commercialized49, one new product added during the quarter
Total multinational customers27, one new North American customer onboarded
Inventory days273 days, reduced from 296 days
Operating cash flow (H1 FY23)₹97 cr, higher than PAT for the period
LOIs and contracts signed₹2,620 cr
Planned CapEx₹670 cr approximately, to be deployed over 18–24 months
FY23 CapEx guidance~₹250 cr
FY24 CapEx guidance~₹350–400 cr
Incremental asset turnover expected1.75x
Incremental ROCE expected20%+
Contracted revenues on six-monthly pricing60–70%
Fundraising via QIP₹500 cr completed
Cash balance₹192 cr